XGN News and Press, Exagen Inc. From 07/29/25

Exagen Inc. (XGN) is expected to report $-0.18 for Q2 2025

CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Board of Directors, effective July 17, 2025. Mr. McKhann is an accomplished leader with over 25 ...

CARLSBAD, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2025, before the market opens on Tuesday, July 29, 2025. John Aballi, Exagen’s President and Chi...

CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chief Scientific Officer. With an extensive background in immunology and autoimmune research, Dr. Mah...

2025-06-20 16:30:54 ET More on Exagen Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability Exagen prices public offering of common stock Exagen prices public offering of commo...

2025-05-11 18:48:14 ET Exagen Inc. (XGN) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 15.92%. The average open to low on the day of earnings was -7.55%. The average open to close on t...

2025-05-11 18:43:14 ET Exagen Inc. (XGN) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in XGN stock price following earnings has averaged ±4.40% , with a median of 3.53%. The single...

CARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,500 shares of its common stock at a public offering price of $5.25 per share on May 8, 2025, p...

2025-05-08 08:56:45 ET More on Exagen Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability Exagen Inc. anticipates $65M revenue for 2025 amid ASP growth and new biomarker launches Exagen announces senior secured credit facility ...

CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3,350,000 shares of its common stock at a public offering price of $5.25 p...